Cholesteryl ester transfer protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Papp, Audrey C ^a   Pinsonneault, Julia K ^a   Wang, Danxin ^a   Newman, Leslie C ^a   Gong, Yan ^b   Johnson, Julie A ^b   Pepine, Carl J ^c   Kumari, Meena ^d   Hingorani, Aroon D ^d   Talmud, Philippa J ^d   Shah, Sonia ^d   Humphries, Steve E ^d   Sadee, Wolfgang ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; ATENOLOL; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; VERAPAMIL;

ADULT; ALTERNATIVE RNA SPLICING; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL ESTER TRANSFER PROTEIN GENE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EXON; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; HYPERTENSION; INTRON; MALE; MORTALITY; PROTEIN SECRETION; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; ALLELE; BLOOD; CARDIOVASCULAR DISEASE; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; LIVER; METABOLISM; MIDDLE AGED; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA SPLICING; SEXUAL DEVELOPMENT;

ADULT; ALLELES; ATENOLOL; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA SPLICING; RNA, MESSENGER; SEX CHARACTERISTICS; VERAPAMIL;

EID: 84863259244     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031930     Document Type: Article

References (38)

1. Brousseau M, Schaefer E, Wolfe M, Bloedon L, Digenio A, et al. (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505-1515.
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122.
3. Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, et al. (2007) ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122.
4. Zhong S, Sharp D, Grove J, Bruce C, Yano K, et al. (1996) Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97: 2917-2923.
5. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, et al. (2009) Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 120: 2414-2420.
6. Corella D, Saiz C, Guillen M, Portoles O, Mulet F, et al. (2000) Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population. Atherosclerosis 152: 367-376.
7. Ordovas J, Cupples L, Corella D, Otvos J, Osgood D, et al. (2000) Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. Arterioscler Thromb Vasc Biol 20: 1323-1329.
8. Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, et al. (2000) Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet Epidem 19: 64-80.
9. Bauerfeind A, Knoblauch H, Schuster H, Luft FC, Reich JG, (2002) Single nucleotide polymorphism haplotypes in the cholesteryl-ester transfer protein (CETP) gene and lipid phenotypes. Hum Hered 54: 166-173.
10. Anguelova M, Benkelfat C, Turecki G, (2003) A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol Psychiatry 8: 574-591.
11. Lu H, Inazu A, Moriyama Y, Higashikata T, Kawashiri M, et al. (2003) Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism. J Mol Med 81: 246-255.
12. Boekholdt S, Sacks F, Jukema JW, Shepherd J, Freeman D, et al. (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111: 278-287.
13. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, et al. (1998) The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl Med 338: 86-93.
14. Carlquist J, Muhlestein J, Horne B, Hart N, Bair T, et al. (2003) The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J 146: 929-931.
15. Regieli JJ, Jukema JW, Grobbee DE, Kastelein JJ, Kuivenhoven JA, et al. (2008) CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur Heart J 29: 2792-2799.
16. Klerkx A, de Grooth G, Zwinderman A, Jukema J, Kuivenhoven J, et al. (2004) Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 34: 21-28.
17. de Grooth G, Zerba K, Huang S, Tsuchihashi Z, Kirchgessner T, et al. (2004) The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J Am Coll Cardiol 43: 854-857.
18. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, et al. (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111: 278-287.
19. Lira ME, Loomis AK, Paciga SA, Lloyd DB, Thompson JF, (2008) Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences. J Lipid Res 49: 1955-1962.
20. Spielmann N, Leon AS, Rao DC, Rice T, Skinner JS, et al. (2007) CETP genotypes and HDL-cholesterol phenotypes in the HERITAGE Family Study. Physiol Genomics 31: 25-31.
21. Frisdal E, Klerkx AH, Le Goff W, Tanck MW, Lagarde JP, et al. (2005) Functional interaction between-629C/A,-971G/A and-1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study. Hum Mol Genet 14: 2607-2618.
22. McCaskie PA, Beilby JP, Chapman CM, Hung J, McQuillan BM, et al. (2007) Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease. Hum Genet 121: 401-411.
23. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56-65.
24. Chasman DI, Pare G, Mora S, Hopewell JC, Peloso G, et al. (2009) Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 5: e1000730.
25. Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, et al. (2009) Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet 85: 628-642.
26. Inazu A, Quinet E, Wang S, Brown M, Stevenson S, et al. (1992) Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein. Biochemistry 31: 2352-2358.
27. Yang T, Agellon L, Walsh A, Breslow J, Tall A, (1996) Alternative splicing of the human cholesteryl ester transfer protein gene in transgenic mice. Exon exclusion modulates gene expression in response to dietary or developmental change. J Biol Chem 271: 12603-12609.
28. Dessi M, Motti C, Cortese C, Leonardis E, Giovannini C, et al. (1997) Alternative splicing of human plasma cholesteryl ester transfer protein mRNA in Caco-2 cells and its modulation by oleic acid. Mol Cell Biochem 177: 107-112.
29. Lambert C, (2004) HelixTree® Genetics Analysis Software. 3.0.6 ed Bozeman, MT Golden Helix, Inc.
30. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, et al. (2007) Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci U S A 104: 20552-20557.
31. Burrows NP, Nicholls AC, Richards AJ, Luccarini C, Harrison JB, et al. (1998) A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families. Am J Hum Genet 63: 390-398.
32. Lange RA, Lindsey ML, (2008) HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Eur Heart J 29: 2708-2709.
33. Marmot MG, Smith GD, Stansfeld S, Patel C, North F, et al. (1991) Health inequalities among British civil servants: the Whitehall II study. Lancet 337: 1387-1393.
34. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, et al. (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. Jama 290: 2805-2816.
35. Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, et al. (2007) KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics 17: 719-729.
36. Miller S, Dykes D, Polesky H, (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
37. Papp A, Pinsonneault J, Cooke G, Sadee W, (2003) Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. Biotechniques 34: 1068-1072.
38. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.